US Patent

US10383884 — 9-aminomethyl minocycline compounds and use thereof in treating community-acquired bacterial pneumonia (CABP)

Method of Use · Assigned to Paratek Pharmaceuticals Inc · Expires 2037-10-31 · 11y remaining

Vulnerability score 62/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-aminomethyl minocycline or a salt thereof.

USPTO Abstract

The invention disclosed herein provides a method for treating Community-Acquired Bacterial Pneumonia (CABP) using 9-[(2,2-dimethyl-propyl amino)-methyl]-minocycline or a salt thereof, in either oral or IV doses or a combination of both.

Drugs covered by this patent

Nuzyra (OMADACYCLINE TOSYLATE) · Paratek Pharms

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-2576`	—	Nuzyra
`U-2576`	—	Nuzyra

Patent Metadata

Patent number: US10383884
Jurisdiction: US
Classification: Method of Use
Expires: 2037-10-31
Drug substance claim: No
Drug product claim: No
Assignee: Paratek Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.